DTech Liquidating

DTech Liquidating Debt/EBITDA

Delisted

Total Debt to EBITDA Ratio of DTech Liquidating (DMTKQ) as of Nov 21, 2026.

Debt/EBITDA

-0.00

YoY

-68.67%

Last updated:

Total Debt to EBITDA Ratio of DTech Liquidating is 2023 -0.00 . Total Debt to EBITDA Ratio of DTech Liquidating was 2022 -0.00 . It decreases by -68.67% higher compared to the previous year.

The DTech Liquidating Debt/EBITDA history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Debt/EBITDA
Date
Debt/EBITDA
Jan 1, 2017
0.00 USD
Jan 1, 2018
0.00 USD
Jan 1, 2019
0.00 USD
Jan 1, 2020
-0.01 USD
Jan 1, 2021
-0.00 USD
Jan 1, 2022
-0.00 USD
Jan 1, 2023
-0.00 USD
The DTech Liquidating Debt/EBITDA history
YEARDebt/EBITDAYoY
-0.00-68.67%
-0.00-56.33%
-0.00-54.41%
-0.01—
0.00—
0.00—
0.00—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

DTech Liquidating Stock analysis

What does DTech Liquidating do? DermTech, Inc. develops and sells non-invasive genomics tests for skin disease diagnosis and treatment, focusing on melanoma detection. The company's primary product, the DermTech Melanoma Test (DMT), marketed as Pigmented Lesion Assay (PLA), analyzes skin samples collected via Smart Stickers to identify genomic markers linked to melanoma. Healthcare providers and dermatologists purchase these tests to assess pigmented skin lesions, addressing unmet needs in diagnosing melanoma early. The company's technology enables non-invasive early detection of higher-risk lesions, reducing unnecessary biopsies. DermTech's commercial test targets the diagnostic pathway for pigmented skin lesions, commonly known as moles, which are dark-colored patches of skin. The firm's focus on inflammatory skin diseases and aging-related skin conditions complements its melanoma detection offerings. By enhancing early melanoma detection through genomic analysis, DermTech provides a solution for clinicians managing skin cancer risks without invasive procedures. The company's products are designed to facilitate clinical assessment of skin lesions that raise melanoma concerns, streamlining the diagnostic process. DermTech's approach to non-invasive testing supports healthcare systems by improving efficiency in skin cancer management. The firm's technology specifically addresses genomic markers associated with melanoma, offering a targeted solution for high-risk lesion identification. DTech Liquidating is one of the most popular companies on Eulerpool.

Frequently Asked Questions about DTech Liquidating stock

On Eulerpool you can find the complete historical development of Total Debt to EBITDA Ratio DTech Liquidating since 2006 – with annual values, charts, and detailed analysis.

Debt/EBITDA measures total debt relative to earnings before interest, taxes, depreciation, and amortization. It indicates the years needed to repay all debt from EBITDA.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Total Debt to EBITDA Ratio's DTech Liquidating with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Leverage — DTech Liquidating

All Key Metrics — DTech Liquidating